VVD 065
Alternative Names: VVD-065Latest Information Update: 08 Feb 2024
At a glance
- Originator Vividion Therapeutics
- Developer Degron Therapeutics; Vividion Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action KEAP1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 Oct 2023 Vividion Therapeutics plans a clinical trial of VVD 065 in Solid tumours
- 11 Oct 2023 Preclinical trials in Solid tumours in USA (PO), prior to October 2023
- 11 Oct 2023 Pharmacodynamics and adverse events data from a preclinical study in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023 2023)